LeMaitre Vascular, Inc.
Rank #246Capital ReturnLMAT · Nasdaq · Healthcare
LeMaitre Vascular, Inc. (LMAT) — Rank #246 by gross profitability (GP/assets 0.28) · ROE 13.7% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001158895 · all metrics point-in-time as of the filing date.
About
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Show moreShow less
The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc.
was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- lemaitre.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-26 | 2024-12-31filed 2025-02-28 | 2023-12-31filed 2024-02-29 | 2022-12-31filed 2023-03-01 |
|---|---|---|---|---|
| Revenue | 249.6 | 219.9 | 193.5 | 161.7 |
| Revenue growth (YoY) | 13.5% | 13.6% | 19.7% | 4.7% |
| Cost of revenue | 71.1 | 69.0 | 66.4 | 56.8 |
| Gross profit | 178.5 | 150.9 | 127.0 | 104.9 |
| Gross margin | 71.5% | 68.6% | 65.7% | 64.9% |
| Research & development | 14.1 | 15.7 | 17.0 | 13.3 |
| Operating income | 67.9 | 52.3 | 36.7 | 26.8 |
| Operating margin | 27.2% | 23.8% | 19.0% | 16.6% |
| Interest income | 13.1 | 4.9 | 3.1 | 1.0 |
| Interest expense | 5.2 | 0.2 | 0.0 | 0.0 |
| Pre-tax income | 75.2 | 56.9 | 39.5 | 27.5 |
| Income tax expense | 17.5 | 12.8 | 9.4 | 6.9 |
| Net income | 57.7 | 44.0 | 30.1 | 20.6 |
| Net margin | 23.1% | 20.0% | 15.6% | 12.8% |
| EPS (basic) | $2.55 | $1.96 | $1.36 | $0.94 |
| EPS (diluted) | $2.52 | $1.93 | $1.34 | $0.93 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?